

AMENDMENTS TO THE CLAIMS

1. (currently amended) A method for reducing the number of metastases in an animal exhibiting a primary tumor comprising administering to said animal a dose of 10 mg/kg to 150 mg/kg of WR-2721 ~~an aminoalkylphosphorothioate or active metabolite thereof~~, wherein the number of metastases is reduced.
2. (canceled)
3. (canceled)
4. (canceled)
5. (canceled)
6. (canceled)
7. (previously presented) The method of claim 1, wherein said tumor is a sarcoma or carcinoma.
8. (canceled)
9. (currently amended) The method claim 1, wherein said WR-2721 ~~aminoalkylphosphorothioate~~ is the thiol form.
10. (currently amended) The method claim 1, wherein said WR-2721 ~~aminoalkylphosphorothioate~~ is the disulfide form.
11. (canceled)

12. (currently amended) The method of claim 1, wherein the route of administration of said WR-2721 aminoalkylphosphorothioate or active metabolite thereof is intravenous, intraperitoneal, intradermal, intramuscular, dermal, nasal, buccal, rectal, vaginal, inhalation, or topical.
13. (currently amended) The method of claim 1, wherein said WR-2721 aminoalkylphosphorothioate or active metabolite thereof is formulated into solutions, suspensions, tablets, pills, capsules, sustained release formulations, powders, creams, ointments, salves, sprays, pumps, liposomes, suppositories, inhalers, and patches.
- 14 – 22 (canceled)
23. (currently amended) The method of claim 1, further comprising monitoring the ability of the dose of WR-2721 an aminoalkylphosphorothioate or active metabolite to reduce metastases in the animal.
24. (previously presented) The method of claim 23, wherein the monitoring comprises measuring the level of angiostatin stimulation.
25. (previously presented) The method of claim 23, wherein the monitoring comprises measuring the level of activity of a matrix metalloproteinase.
26. (previously presented) The method of claim 25, wherein the matrix metalloproteinase is MMP-2.
27. (previously presented) The method of claim 25, wherein the matrix metalloproteinase is MMP-9.
28. (previously presented) The method of claim 23, wherein the monitoring comprising measuring the stimulation of MnSOD.

29. (previously presented) The method of claim 28, wherein the measuring of MnSOD stimulation comprises measuring the stimulation of MnSOD gene expression.
30. (currently amended) A method for inhibiting metastasis in an animal exhibiting a primary tumor comprising administering to said animal a dose of 10 mg/kg to 150 mg/kg of WR-2721~~an aminoalkylphosphorothioate or active metabolite thereof~~, wherein the number of metastases is inhibited.
31. (currently amended) A method for preventing metastasis in an animal exhibiting a primary tumor comprising administering to said animal a dose of 10 mg/kg to 150 mg/kg of WR-2721~~an aminoalkylphosphorothioate or active metabolite thereof~~, and wherein metastases are prevented in said animal.
32. (canceled)
33. (canceled)
34. (previously presented) The method of claim 1, wherein the dose is about 50 mg/kg to 100 mg/kg.